CD8A and cancer: Suggesting a mechanism by which Y9 functions as a co-stimulator, activating effector immune cells such as NK cells, CD8+ T cells, and APCs, while J43 and MPDL3280a provide protection to immune cells against cell-to-cell contact inhibition caused by cancer cells, T-regs, and MDSCs.